Oncology Highlights – 30/07/2018
Oncology Highlights – 30/07/2018
Navigating the Healthcare Horizon: Odyssey of Mergers, Funding, a...
Merck’s KEYTRUDA as Adjuvant Therapy for RCC Patients; BMS Receiv...
Samsung Partnered with Lunit; Boston Scientific Launched VersaVue...
Key Updates on Phase 1 Trial of AB-1005 Gene Therapy for Multiple...

Search by Categories

Home / Blog / Notizia

Notizia - Recent Pharma, Healthcare and Biotech Happenings

iVEAcare’s $27.5 Million Series A Funding; AI M...

iVEAcare Launched $27.5 Million Series A Funding from Leading Medtech Investors On April 24, 2024, iVEAcare, announced the closure of a $27.5 million Series A financing. The financing was led by Ve...

Apr 25, 2024

medtech-news-for-iveacare-cerenovus-cochlear-immunovia
pharma-news-for-ipsen-synox-roche-abbvie
Ipsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Trial; Roche’s Alecensa FDA Approval; AbbVie’s RINVOQ Phase III SELECT-GCA Trial; AskBio’s AB-1002 FDA Fast Track Designation

Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the ...

Find More
medtech-news-for-baxter-bayer-hologic-labcorp
Baxter Introduced New Injectable Pharmaceuticals to US Market; Bayer and Hologic Collaborated to Deliver Contrast-Enhanced Mammography; Labcorp Received FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit; Onkos Surgical Won FDA De Novo Nod For Antibacterial-Coated Orthopedic Implants; Heartbeam Presented Positive Results On Its Artificial Intelligence Capabilities For Detecting Arrhythmias; Cognito Therapeutics Showed Positive Non-Invasive Neuromod Results 

Baxter Introduced New Injectable Pharmaceuticals to US Market On April 11, 2024, the pharmaceutical portfolio of multinational medical goods corporation Baxter International Inc. was augmented with the introduction of five new injectable medications in the US market. The goods were made to fulfill essential dema...

Find More
pharma-news-for-roche-novartis-vertex-telix
Roche’s Columvi Phase III STARGLO Trial; Novartis’ Fabhalta Latest Data; Vertex’s Alpine Immune Sciences Acquisition; Telix Pharmaceuticals’ TLX101-CDx Fast Track Designation; NovelMed’s NM5072 Orphan Drug Designation

Roche's Columvi Achieves Primary Endpoint of Prolonged Overall Survival in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Trial Roche reported that the Phase III STARGLO trial successfully achieved its main goal of improving overall survival. The research revealed that in...

Find More

More Views & Analysis

medtech-news-for-carl-zeiss-abbott-medtronic-edwards
Carl Zeiss Meditec AG’s Acquisition of Dutch Ophthalmic Research Center; Johnson & Johnson’s Shockwave Medical Acquisition; Biora Therapeutics’ BT-600 Positive Results; Medtronic’s Single-Shot Mapping Ablation Catheter Positive Data; Abbott’s TriClip FDA Approval; Abbott’s Whole Blood Rapid Test FDA Clearance

Carl Zeiss Meditec AG Completed Acquisition of Dutch Ophthalmic Research Center (D.O.R.C); Companies Unite to Shape Ophthalmology Market  On April 04, 2024, Carl Zeiss Meditec AG announced that it acquired D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France. T...

Find More
pharma-news-for-astrazeneca-daiichi-sankyo-basilea-genmab
AstraZeneca and Daiichi Sankyo’s Enhertu US Approval; Basilea’s ZEVTERA FDA Approval; Genmab’s ProfoundBio Acquisition; Rocket Pharmaceuticals’ RP-L102 EMA Approval; Alexion’s Ultomiris and Soliris AAN 2024 Data

Enhertu Receives US Approval as First HER2-focused Treatment for Metastatic Solid Tumors, Independent of Tumor Origin AstraZeneca and Daiichi Sankyo's drug Enhertu (trastuzumab deruxtecan) has gained approval in the United States for treating adult patients with inoperable or metastatic HER2-positive (IHC 3+) so...

Find More
medtech-news-for-c2dx- abbott- medtronic-nexalin
C2Dx’s Shaw Scalpel System; Texas Original’s RSO Gummies; Abbott’s Whole Blood Rapid Test FDA Clearance; Medtronic’s TAVR Device FDA Clearance; Nexalin’s Device Improved Symptoms; CYduct Diagnostics’ Positive Study Results

C2Dx Launched Next Generation Shaw Scalpel System  On March 26, 2024, C2Dx, a privately-owned medical device company, announced the launch of its Next Generation Shaw Scalpel System. The Shaw Scalpel System has obtained 510(k) clearance from the FDA for the upgraded controller of its advanced surgical techn...

Find More
pharma-news-for-bms-astrazeneca-astellas-akebia
AstraZeneca’s Voydeya FDA Approval; Akebia’s Vafseo FDA Approval; Bristol Myers Squibb’s Phase III YELLOWSTONE Trial Update; Astellas’ IZERVAY FDA Approval; AstraZeneca’s Truqap and Faslodex MHLW Approval

Voydeya Receives FDA Approval as Supplemental Treatment with Ravulizumab or Eculizumab for Managing Extravascular Hemolysis in Adult Patients with PNH Voydeya (danicopan) has received approval in the United States for use alongside ravulizumab or eculizumab in treating extravascular hemolysis (EVH) in adults dia...

Find More
medtech-news-for-tela-bio-stryker-livanova-c2dx
TELA Bio Launched Hernia Mesh Fixation Devices; Stryker Acquisition of SERF SAS; FDA 510(k) Clearance for RedDrop Dx’s Blood Collection Device; FDA 510(k) Clearance for Next Generation Shaw Scalpel; LivaNova’s Sleep Apnoea Device Trial; Nanodropper’s Positive Impact on Glaucoma Treatment

TELA Bio Launched FDA-approved Hernia Mesh Fixation Devices  On March 21, 2024, TELA Bio, Inc., a medical technology firm, launched its FDA-approved LIQUIFIX devices for hernia repairs in the United States. The LIQUIFIX FIX8™ and LIQUIFIX Precision™ are specifically engineered for laparoscopic and open femo...

Find More
pharma-news-for-regeneron-novartis-novo-nordisk-abbvie
Regeneron’s Odronextamab BLA; Novo Nordisk’s Cardior Pharmaceuticals Acquisition; Novartis’ Fabhalta CHMP Approval; Idorsia’s TRYVIO FDA Approval; AbbVie’s Landos Biopharma Acquisition

Regeneron Updates Progress on Biologics License Application for Odronextamab Regeneron Pharmaceuticals, Inc. has announced that the FDA has issued Complete Response Letters (CRLs) regarding the Biologics License Application (BLA) for odronextamab in cases of relapsed/refractory (R/R) follicular lymphoma (FL) and...

Find More

An inherited disorder, Von Hippel-Lindau (VHL) syndrome is characterized by the formation of tumors .....

Find More

Multiple myeloma (MM) is a cancer of the blood that begins in the bone marrow. In myeloma, plasma ce.....

Find More

Diabetic macular edema (DME) is an eye disease in which there is fluid buildup in the macula. Even t.....

Find More

Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Se.....

Find More

Uremic Pruritusis also known as chronic kidney disease-associated pruritus (CKD-aP), is a chronic it.....

Find More

Diabetic retinopathy is an eye condition that leads to vision loss and blindness in people who have .....

Find More